Alfredo Fusco

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8775899/alfredo-fusco-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

351 papers	18,896 citations	72 h-index	120 g-index
358 ext. papers	20,323 ext. citations	6.9 avg, IF	6.13 L-index

#	Paper	IF	Citations
351	The role of HMGA1 protein in gastroenteropancreatic neuroendocrine tumors.. *Cell Cycle*, **2022**, 1-12	4.7	0
350	HMGA1 induces EZH2 overexpression in human B-cell lymphomas. *American Journal of Cancer Research*, **2021**, 11, 2174-2187	4.4	
349	Critical role of the high mobility group A proteins in hematological malignancies. *Hematological Oncology*, **2021**,	1.3	1
348	MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells. *Cell Cycle*, **2021**, 20, 716-729	4.7	0
347	Interplay between HMGA and TP53 in cell cycle control along tumor progression. *Cellular and Molecular Life Sciences*, **2021**, 78, 817-831	10.3	4
346	HMGA1-Regulating microRNAs Let-7a and miR-26a are Downregulated in Human Seminomas. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	13
345	The Long Non-Coding RNA () Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity. *Cancers*, **2020**, 12,	6.6	23
344	HMGA1-pseudogene7 transgenic mice develop B cell lymphomas. *Scientific Reports*, **2020**, 10, 7057	4.9	6
343	RPSAP52 lncRNA Inhibits p21Waf1/CIP Expression by Interacting With the RNA Binding Protein HuR. *Oncology Research*, **2020**, 28, 191-201	4.8	8
342	The shows oncogenic activity. *Cell Cycle*, **2020**, 19, 2955-2959	4.7	1
341	Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. *Scientific Reports*, **2020**, 10, 18850	4.9	12
340	Characterization of transgenic mouse embryonic fibroblasts. *Cell Cycle*, **2020**, 19, 2281-2285	4.7	1
339	Emerging Role of USP8, HMGA, and Non-Coding RNAs in Pituitary Tumorigenesis. *Cancers*, **2019**, 11,	6.6	3
338	A ceRNA Circuitry Involving the Long Noncoding RNA Klhl14-AS, Pax8, and Bcl2 Drives Thyroid Carcinogenesis. *Cancer Research*, **2019**, 79, 5746-5757	10.1	16
337	Double knock-out of Hmga1 and Hipk2 genes causes perinatal death associated to respiratory distress and thyroid abnormalities in mice. *Cell Death and Disease*, **2019**, 10, 747	9.8	3
336	The () Gene Acts as Tumor Suppressor in Breast Cancer. *Cancers*, **2019**, 11,	6.6	7
335	HMGA1 negatively regulates NUMB expression at transcriptional and post transcriptional level in glioblastoma stem cells. *Cell Cycle*, **2019**, 18, 1446-1457	4.7	18

334	Overexpression of Figures as a Potential Prognostic Factor in Endometrioid Endometrial Carcinoma (EEC). *Genes*, **2019**, 10,	4.2	16
333	RPSAP52 lncRNA is overexpressed in pituitary tumors and promotes cell proliferation by acting as miRNA sponge for HMGA proteins. *Journal of Molecular Medicine*, **2019**, 97, 1019-1032	5.5	43
332	The complex CBX7-PRMT1 has a critical role in regulating E-cadherin gene expression and cell migration. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2019**, 1862, 509-521	6	12
331	HMGA and Cancer: A Review on Patent Literatures. *Recent Patents on Anti-Cancer Drug Discovery*, **2019**, 14, 258-267	2.6	12
330	Characterization of inflammatory infiltrate of ulcerative dermatitis in C57BL/6NCrl-Tg(HMGA1P6)1Pg mice. *Laboratory Animals*, **2019**, 53, 447-458	2.6	9
329	Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2019**, 15, 231-242	6	3
328	Ionizing Radiation Deregulates the MicroRNA Expression Profile in Differentiated Thyroid Cells. *Thyroid*, **2018**, 28, 407-421	6.2	7
327	HMGA2, but not HMGA1, is overexpressed in human larynx carcinomas. *Histopathology*, **2018**, 72, 1102-1114	7.34	16
326	UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1. *Genes*, **2018**, 9,	4.2	28
325	Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene. *Cancers*, **2018**, 10,	6.6	5
324	The Long Non-Coding RNA and Its Associated-Gene Are Down-Regulated in Human Thyroid Neoplasias and Act as Tumour Suppressors. *Cancers*, **2018**, 10,	6.6	9
323	The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells. *Oncotarget*, **2018**, 9, 23334-23348	3.3	9
322	HMGA2 cooperates with either p27 deficiency or Cdk4 mutation in pituitary tumorigenesis. *Cell Cycle*, **2018**, 17, 580-588	4.7	8
321	Retraction: High-Mobility Group A1 Proteins Regulate p53-Mediated Transcription of Gene. *Cancer Research*, **2018**, 78, 6905	10.1	
320	Retraction: HMGA Proteins Up-regulate Gene in Mouse and Human Pituitary Adenomas. *Cancer Research*, **2018**, 78, 6906	10.1	2
319	Retraction: The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins. *Cancer Research*, **2018**, 78, 6907	10.1	
318	Retraction: Haploinsufficiency of the Gene Causes Cardiac Hypertrophy and Myelo-Lymphoproliferative Disorders in Mice. *Cancer Research*, **2018**, 78, 6908	10.1	
317	Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model. *International Journal of Cancer*, **2017**, 140, 2150-2161	7.5	18

316	Identification and Synthesis of Mycalol Analogues with Improved Potency against Anaplastic Thyroid Carcinoma Cell Lines. *Journal of Natural Products*, **2017**, 80, 1125-1133	4.9	3
315	High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. *Molecular Carcinogenesis*, **2017**, 56, 2146-2157	5	15
314	Critical role of HMGA proteins in cancer cell chemoresistance. *Journal of Molecular Medicine*, **2017**, 95, 353-360	5.5	16
313	Role of Dicer1 in thyroid cell proliferation and differentiation. *Cell Cycle*, **2017**, 16, 2282-2289	4.7	11
312	High mobility group A1 protein modulates autophagy in cancer cells. *Cell Death and Differentiation*, **2017**, 24, 1948-1962	12.7	30
311	miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene. *BMC Cancer*, **2017**, 17, 170	4.8	18
310	The HMGA1 Pseudogene 7 Induces miR-483 and miR-675 Upregulation by Activating Egr1 through a ceRNA Mechanism. *Genes*, **2017**, 8,	4.2	19
309	A novel splice variant of the protein tyrosine phosphatase PTPRJ that encodes for a soluble protein involved in angiogenesis. *Oncotarget*, **2017**, 8, 10091-10102	3.3	5
308	HMGA1 overexpression is associated with a particular subset of human breast carcinomas. *Journal of Clinical Pathology*, **2016**, 69, 117-21	3.9	12
307	HMGA1P7-pseudogene regulates H19 and Igf2 expression by a competitive endogenous RNA mechanism. *Scientific Reports*, **2016**, 6, 37622	4.9	28
306	HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models. *Neoplasia*, **2016**, 18, 724-731	6.4	25
305	Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression. *Cancer Research*, **2016**, 76, 5080-91	10.1	23
304	Hmga1 null mouse embryonic fibroblasts display downregulation of spindle assembly checkpoint gene expression associated to nuclear and karyotypic abnormalities. *Cell Cycle*, **2016**, 15, 812-8	4.7	6
303	UbcH10 overexpression is less pronounced in older colorectal cancer patients. *International Journal of Colorectal Disease*, **2016**, 31, 1367-8	3	3
302	UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines. *Oncotarget*, **2016**, 7, 65876-65887	3.3	26
301	HMGA1-pseudogenes and cancer. *Oncotarget*, **2016**, 7, 28724-35	3.3	31
300	HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma. *Oncotarget*, **2016**, 7, 25872-84	3.3	20
299	UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients. *Molecular Carcinogenesis*, **2016**, 55, 793-807	5	18

298	PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells. *Scientific Reports*, **2016**, 6, 25268	4.9	9
297	A polymorphism of HMGA1 protects against proliferative diabetic retinopathy by impairing HMGA1-induced VEGFA expression. *Scientific Reports*, **2016**, 6, 39429	4.9	30
296	Hmga2 is necessary for Otx2-dependent exit of embryonic stem cells from the pluripotent ground state. *BMC Biology*, **2016**, 14, 24	7.3	19
295	HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 1169-79	6.4	29
294	High Mobility Group A proteins in esophageal carcinomas. *Cell Cycle*, **2016**, 15, 2410-3	4.7	9
293	MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. *Expert Opinion on Therapeutic Targets*, **2015**, 19, 1017-26	6.4	55
292	Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. *Cell Cycle*, **2015**, 14, 2590-7	4.7	42
291	The R3 receptor-like protein tyrosine phosphatase subfamily inhibits insulin signalling by dephosphorylating the insulin receptor at specific sites. *Journal of Biochemistry*, **2015**, 158, 235-43	3.1	12
290	HMGA1-pseudogene expression is induced in human pituitary tumors. *Cell Cycle*, **2015**, 14, 1471-5	4.7	45
289	Expression of CD133 in differentiated thyroid cancer of young patients. *Journal of Clinical Pathology*, **2015**, 68, 434-40	3.9	7
288	Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2015**, 388, 1179-86	3.4	20
287	2-Iodohexadecanal inhibits thyroid cell growth in part through the induction of let-7f microRNA. *Molecular and Cellular Endocrinology*, **2015**, 414, 224-32	4.4	3
286	High mobility group a proteins as tumor markers. *Frontiers in Medicine*, **2015**, 2, 15	4.9	85
285	Epigenetic Mechanisms Leading to Overexpression of HMGA Proteins in Human Pituitary Adenomas. *Frontiers in Medicine*, **2015**, 2, 39	4.9	25
284	Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors. *Frontiers in Medicine*, **2015**, 2, 54	4.9	26
283	CBX7 and HMGA1b proteins act in opposite way on the regulation of the SPP1 gene expression. *Oncotarget*, **2015**, 6, 2680-92	3.3	19
282	The "next-generation" knowledge of papillary thyroid carcinoma. *Cell Cycle*, **2015**, 14, 2018-21	4.7	10
281	miR-130b-3p Upregulation Contributes to the Development of Thyroid Adenomas Targeting CCDC6 Gene. *European Thyroid Journal*, **2015**, 4, 213-21	4.2	10

280	Inhibitory effects of 2-iodohexadecanal on FRTL-5 thyroid cells proliferation. *Molecular and Cellular Endocrinology*, **2015**, 404, 123-31	4.4	4
279	miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E59-69	5.6	38
278	The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias. *Cancer Letters*, **2015**, 357, 535-41	9.9	9
277	PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration. *Oncotarget*, **2015**, 6, 5310-23	3.3	39
276	Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer. *Oncotarget*, **2015**, 6, 19328-35	3.3	14
275	HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. *Oncotarget*, **2015**, 6, 10320-34	3.3	20
274	New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma. *Oncotarget*, **2015**, 6, 11242-51	3.3	39
273	Polycomb protein family member CBX7 plays a critical role in cancer progression. *American Journal of Cancer Research*, **2015**, 5, 1594-601	4.4	25
272	Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity. *Oncotarget*, **2015**, 6, 15628-38	3.3	20
271	Deregulation of HMGA1 expression induces chromosome instability through regulation of spindle assembly checkpoint genes. *Oncotarget*, **2015**, 6, 17342-53	3.3	19
270	Deregulation of microRNA expression in thyroid neoplasias. *Nature Reviews Endocrinology*, **2014**, 10, 88-101	15.2	86
269	Mir-23b and miR-130b expression is downregulated in pituitary adenomas. *Molecular and Cellular Endocrinology*, **2014**, 390, 1-7	4.4	70
268	NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. *Molecular Cell*, **2014**, 55, 123-37	17.6	36
267	CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas). *European Thyroid Journal*, **2014**, 3, 211-6	4.2	5
266	CBX7 modulates the expression of genes critical for cancer progression. *PLoS ONE*, **2014**, 9, e98295	3.7	21
265	Structural model of the hUbA1-UbcH10 quaternary complex: in silico and experimental analysis of the protein-protein interactions between E1, E2 and ubiquitin. *PLoS ONE*, **2014**, 9, e112082	3.7	5
264	POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation.. *Journal of Biological Chemistry*, **2014**, 289, 14966	5.4	78
263	HMGA1-pseudogene overexpression contributes to cancer progression. *Cell Cycle*, **2014**, 13, 3636-9	4.7	33

262	Hmga1/Hmga2 double knock-out mice display a "superpygmy" phenotype. *Biology Open*, **2014**, 3, 372-8	2.2	39
261	CBX7 gene expression plays a negative role in adipocyte cell growth and differentiation. *Biology Open*, **2014**, 3, 871-9	2.2	13
260	High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. *BMC Cancer*, **2014**, 14, 851	4.8	30
259	Corrigendum to "The high mobility group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression" [Mol. Oncol. 7 (3) (Jan. 2013) 531–542]. *Molecular Oncology*, **2014**, 8, 159-159	7.9	1
258	High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. *Journal of Cellular Physiology*, **2014**, 229, 53-9	7	29
257	HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels. *Oncotarget*, **2014**, 5, 3234-45	3.3	58
256	HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs. *Oncotarget*, **2014**, 5, 8341-54	3.3	66
255	Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328. *FEBS Journal*, **2013**, 280, 401-12	5.7	22
254	Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation. *ACS Chemical Biology*, **2013**, 8, 1497-506	4.9	23
253	Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 2834-43	5.6	24
252	Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors. *BMC Cancer*, **2013**, 13, 433	4.8	23
251	UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. *European Journal of Cancer*, **2013**, 49, 1117-26	7.5	20
250	Embryonic defects and growth alteration in mice with homozygous disruption of the Patz1 gene. *Journal of Cellular Physiology*, **2013**, 228, 646-53	7	25
249	The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression. *Molecular Oncology*, **2013**, 7, 531-42	7.9	32
248	Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of histone deacetylase inhibitors on ras-transformed thyroid cells. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E1031-40	5.6	4
247	The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. *European Journal of Cancer*, **2013**, 49, 1142-51	7.5	24
246	A miRNA signature associated with human metastatic medullary thyroid carcinoma. *Endocrine-Related Cancer*, **2013**, 20, 809-23	5.7	69
245	DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy. *Oncology Letters*, **2013**, 6, 86-90	2.6	16

244	Mycalol: A Natural Lipid with Promising Cytotoxic Properties against Human Anaplastic Thyroid Carcinoma Cells. *Angewandte Chemie*, **2013**, 125, 9426-9430	3.6	2
243	Mycalol: a natural lipid with promising cytotoxic properties against human anaplastic thyroid carcinoma cells. *Angewandte Chemie - International Edition*, **2013**, 52, 9256-60	16.4	13
242	Pituitary Adenoma: Role of HMGA Proteins **2013**, 161-168		
241	Tumor suppressor activity of CBX7 in lung carcinogenesis. *Cell Cycle*, **2012**, 11, 1888-91	4.7	25
240	Isolation and functional characterization of peptide agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor suppressor activity. *ACS Chemical Biology*, **2012**, 7, 1666-76	4.9	27
239	HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. *Molecular Cell*, **2012**, 47, 87-98	17.6	47
238	The high-mobility group A1-estrogen receptor nuclear interaction is impaired in human testicular seminomas. *Journal of Cellular Physiology*, **2012**, 227, 3749-55	7	36
237	Thyrotropin regulates thyroid cell proliferation by up-regulating miR-23b and miR-29b that target SMAD3. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 3292-301	5.6	26
236	Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXYD5 (Dysadherin) gene. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E2168-78	5.6	23
235	Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E710-8	5.6	91
234	The HMGA1-IGF-I/IGFBP system: a novel pathway for modulating glucose uptake. *Molecular Endocrinology*, **2012**, 26, 1578-89		31
233	Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage. *PLoS ONE*, **2012**, 7, e36177	3.7	27
232	High mobility group A-interacting proteins in cancer: focus on chromobox protein homolog 7, homeodomain interacting protein kinase 2 and PATZ. *Journal of Nucleic Acids Investigation*, **2012**, 3, 1		5
231	HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. *Histopathology*, **2012**, 60, 397-404	7.3	66
230	PIT1 upregulation by HMGA proteins has a role in pituitary tumorigenesis. *Endocrine-Related Cancer* , **2012**, 19, 123-35	5.7	28
229	CBX7 is a tumor suppressor in mice and humans. *Journal of Clinical Investigation*, **2012**, 122, 612-23	15.9	114
228	CDH16/Ksp-cadherin is expressed in the developing thyroid gland and is strongly down-regulated in thyroid carcinomas. *Endocrinology*, **2012**, 153, 522-34	4.8	32
227	POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation. *Journal of Biological Chemistry*, **2012**, 287, 18308-17	5.4	14

226	Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E1128-38	5.6	116
225	Oncogenic alterations in papillary thyroid cancers of young patients. *Thyroid*, **2012**, 22, 17-26	6.2	58
224	High-mobility group A1 protein: a new coregulator of peroxisome proliferator-activated receptor-mediated transrepression in the vasculature. *Circulation Research*, **2012**, 110, 394-405	15.7	10
223	Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity. *PLoS ONE*, **2012**, 7, e49298	3.7	10
222	Expression of a truncated Hmga1b gene induces gigantism, lipomatosis and B-cell lymphomas in mice. *European Journal of Cancer*, **2011**, 47, 470-8	7.5	8
221	TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. *European Journal of Cancer*, **2011**, 47, 926-33	7.5	60
220	Down-regulation of oestrogen receptor-associates with transcriptional co-regulator PATZ1 delocalization in human testicular seminomas. *Journal of Pathology*, **2011**, 224, 110-20	9.4	37
219	miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, E1915-24	5.6	48
218	A TSH-CREB1-microRNA loop is required for thyroid cell growth. *Molecular Endocrinology*, **2011**, 25, 1819-30		28
217	TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, E772-81	5.6	34
216	Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 1029-38	5.6	53
215	MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, E1388-98	5.6	95
214	Functional variants of the HMGA1 gene and type 2 diabetes mellitus. *JAMA - Journal of the American Medical Association*, **2011**, 305, 903-12	27.4	72
213	Homeodomain-interacting protein kinase-2 stabilizes p27(kip1) by its phosphorylation at serine 10 and contributes to cell motility. *Journal of Biological Chemistry*, **2011**, 286, 29005-29013	5.4	9
212	The Camp-HMGA1-RBP4 System **2011**, 175-197		
211	Role of PTPRJ genotype in papillary thyroid carcinoma risk. *Endocrine-Related Cancer*, **2010**, 17, 1001-6	5.7	24
210	High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene. *Cancer Research*, **2010**, 70, 5379-88	10.1	50
209	Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. *Endocrine-Related Cancer*, **2010**, 17, 989-99	5.7	34

208	Role of the high mobility group A proteins in the regulation of pituitary cell cycle. *Journal of Molecular Endocrinology*, **2010**, 44, 309-18	4.5	25
207	Increased BDNF promoter methylation in the Wernicke area of suicide subjects. *Archives of General Psychiatry*, **2010**, 67, 258-67		294
206	Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. *Genes and Cancer*, **2010**, 1, 210-24	2.9	62
205	Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. *Endocrine-Related Cancer*, **2010**, 17, F91-104	5.7	75
204	HMGA2: A pituitary tumour subtype-specific oncogene?. *Molecular and Cellular Endocrinology*, **2010**, 326, 19-24	4.4	54
203	HMGA1 protein expression in familial breast carcinoma patients. *European Journal of Cancer*, **2010**, 46, 332-9	7.5	16
202	Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. *European Journal of Cancer*, **2010**, 46, 1438-44	7.5	73
201	The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. *European Journal of Cancer*, **2010**, 46, 2304-13	7.5	65
200	HMGA and cancer. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2010**, 1799, 48-54	6	113
199	UbcH10 expression on thyroid fine-needle aspirates. *Cancer Cytopathology*, **2010**, 118, 157-65	3.9	18
198	FEZ1/LZTS1 protein expression in ovarian cancer. *Journal of Cellular Physiology*, **2010**, 222, 382-6	7	11
197	Targeted disruption of the murine homeodomain-interacting protein kinase-2 causes growth deficiency in vivo and cell cycle arrest in vitro. *DNA and Cell Biology*, **2009**, 28, 161-7	3.6	16
196	The eighth fibronectin type III domain of protein tyrosine phosphatase receptor J influences the formation of protein complexes and cell localization. *Journal of Biochemistry*, **2009**, 145, 377-85	3.1	12
195	Interaction between HMGA1 and retinoblastoma protein is required for adipocyte differentiation. *Journal of Biological Chemistry*, **2009**, 284, 25993-6004	5.4	14
194	The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. *Cancer Research*, **2009**, 69, 1867-76	10.1	69
193	Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice. *Endocrine-Related Cancer*, **2009**, 16, 483-90	5.7	11
192	HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. *Cancer Research*, **2009**, 69, 1844-50	10.1	98
191	Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. *Cancer Research*, **2009**, 69, 7079-87	10.1	69

190	The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis. *BMC Biology*, **2009**, 7, 24	7.3	34
189	UbcH10 expression in human lymphomas. *Histopathology*, **2009**, 54, 731-40	7.3	31
188	Hmga1 null mice are less susceptible to chemically induced skin carcinogenesis. *European Journal of Cancer*, **2008**, 44, 318-25	7.5	5
187	HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. *European Journal of Cancer*, **2008**, 44, 1015-21	7.5	58
186	HMGA1 protein is a novel target of the ATM kinase. *European Journal of Cancer*, **2008**, 44, 2668-79	7.5	19
185	Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. *Cancer Research*, **2008**, 68, 6770-8	10.1	91
184	siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. *Nucleic Acids Research*, **2008**, 36, 6944-6944	20.1	4
183	siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. *Nucleic Acids Research*, **2008**, 36, e2	20.1	49
182	Low-resolution structure and fluorescence anisotropy analysis of protein tyrosine phosphatase eta catalytic domain. *Biophysical Journal*, **2007**, 92, 4424-32	2.9	12
181	20 years of RET/PTC in thyroid cancer: clinico-pathological correlations. *Arquivos Brasileiros De Endocrinologia E Metabologia*, **2007**, 51, 731-5		21
180	New drugs in thyroid cancer. *Arquivos Brasileiros De Endocrinologia E Metabologia*, **2007**, 51, 857-61		4
179	Identification of new high mobility group A1 associated proteins. *Proteomics*, **2007**, 7, 3735-42	4.8	8
178	Roles of HMGA proteins in cancer. *Nature Reviews Cancer*, **2007**, 7, 899-910	31.3	541
177	Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. *EMBO Journal*, **2007**, 26, 1878-90	13	44
176	FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. *BMC Cancer*, **2007**, 7, 17	4.8	40
175	A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. *Cancer Research*, **2007**, 67, 10148-58	10.1	144
174	DNA damage, homology-directed repair, and DNA methylation. *PLoS Genetics*, **2007**, 3, e110	6	138
173	RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. *Cancer Research*, **2007**, 67, 381-90	10.1	45

172	Transcriptional profile of Ki-Ras-induced transformation of thyroid cells. *Cancer Investigation*, **2007**, 25, 256-66	2.1	4
171	The Mia/Cd-rap gene expression is downregulated by the high-mobility group A proteins in mouse pituitary adenomas. *Endocrine-Related Cancer*, **2007**, 14, 875-86	5.7	10
170	Loss of p27 expression through RAS-->BRAF-->MAP kinase-dependent pathway in human thyroid carcinomas. *Cell Cycle*, **2007**, 6, 2817-25	4.7	22
169	An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta. *Molecular Endocrinology*, **2007**, 21, 229-46		21
168	Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. *Endocrinology*, **2007**, 148, 5186-94	4.8	35
167	Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. *Endocrine-Related Cancer*, **2007**, 14, 405-20	5.7	26
166	SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. *Clinical Cancer Research*, **2007**, 13, 2738-44	12.9	34
165	MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. *Endocrine-Related Cancer*, **2007**, 14, 791-8	5.7	341
164	UbcH10 is overexpressed in malignant breast carcinomas. *European Journal of Cancer*, **2007**, 43, 2729-35	7.5	56
163	High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. *Journal of Clinical Investigation*, **2007**, 117, 693-702	15.9	80
162	HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. *Cancer Cell*, **2006**, 9, 459-71	24.3	199
161	Critical role of the HMGA2 gene in pituitary adenomas. *Cell Cycle*, **2006**, 5, 2045-8	4.7	39
160	TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. *Nucleic Acids Research*, **2006**, 34, 364-72	20.1	49
159	The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. *Cancer Research*, **2006**, 66, 6280-7	10.1	42
158	Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer. *Cancer Research*, **2006**, 66, 5085-93	10.1	37
157	Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. *DNA and Cell Biology*, **2006**, 25, 376-82	3.6	46
156	Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. *Cancer Research*, **2006**, 66, 2536-43	10.1	93
155	RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. *European Journal of Endocrinology*, **2006**, 155, 645-53	6.5	154

154	RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 2414-23	5.6	151
153	E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. *Cell Division*, **2006**, 1, 17	2.8	22
152	Crystallization and preliminary X-ray diffraction analysis of rat protein tyrosine phosphatase eta. *Acta Crystallographica Section F: Structural Biology Communications*, **2006**, 62, 923-5		
151	Differential HMGA expression and post-translational modifications in prostatic tumor cells **2005**, 26, 515		
150	Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. *European Journal of Cancer*, **2005**, 41, 816-21	7.5	73
149	Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. *American Journal of Pathology*, **2005**, 166, 737-49	5.8	83
148	Expression, purification, and characterization of rat protein tyrosine phosphatase eta catalytic domain. *Protein Expression and Purification*, **2005**, 41, 113-20	2	6
147	Mutation of the PIK3CA gene in anaplastic thyroid cancer. *Cancer Research*, **2005**, 65, 10199-207	10.1	282
146	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. *Journal of Clinical Investigation*, **2005**, 115, 1068-1081	15.9	214
145	High-mobility-group A1 (HMGA1) proteins down-regulate the expression of the recombination activating gene 2 (RAG2). *Biochemical Journal*, **2005**, 389, 91-7	3.8	12
144	Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. *Nature Medicine*, **2005**, 11, 765-73	50.5	172
143	Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. *Oncogene*, **2005**, 24, 1882-94	9.2	92
142	Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. *Oncogene*, **2005**, 24, 3427-35	9.2	126
141	The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. *Oncogene*, **2005**, 24, 3187-95	9.2	48
140	HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. *Oncogene*, **2005**, 24, 6809-19	9.2	24
139	Familial cancer associated with a polymorphism in ARLTS1. *New England Journal of Medicine*, **2005**, 352, 1667-76	59.2	101
138	Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 928-35	5.6	160
137	Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 4703-9	5.6	34

136	Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. *Carcinogenesis*, **2005**, 26, 1021-34	4.6	52
135	High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. *Endocrine-Related Cancer*, **2005**, 12, 867-74	5.7	35
134	IFN-gamma gene expression is controlled by the architectural transcription factor HMGA1. *International Immunology*, **2005**, 17, 297-306	4.9	10
133	A new mechanism of BRAF activation in human thyroid papillary carcinomas. *Journal of Clinical Investigation*, **2005**, 115, 20-23	15.9	18
132	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. *Journal of Clinical Investigation*, **2005**, 115, 1068-81	15.9	108
131	A new mechanism of BRAF activation in human thyroid papillary carcinomas. *Journal of Clinical Investigation*, **2005**, 115, 20-3	15.9	6
130	Differential HMGA expression and post-translational modifications in prostatic tumor cells. *International Journal of Oncology*, **2005**, 26, 515-20	1	5
129	Minireview: RET: normal and abnormal functions. *Endocrinology*, **2004**, 145, 5448-51	4.8	134
128	Identification of the genes up- and down-regulated by the high mobility group A1 (HMGA1) proteins: tissue specificity of the HMGA1-dependent gene regulation. *Cancer Research*, **2004**, 64, 5728-35	10.1	41
127	The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation. *Journal of Biological Chemistry*, **2004**, 279, 29004-12	5.4	48
126	Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. *Cancer Research*, **2004**, 64, 3823-9	10.1	40
125	Phosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytes. *Molecular Biology of the Cell*, **2004**, 15, 1224-32	3.5	72
124	HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. *Clinical Cancer Research*, **2004**, 10, 7637-44	12.9	64
123	Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy. *Journal of Molecular Endocrinology*, **2004**, 33, 133-43	4.5	21
122	Akt-Dependent T198 Phosphorylation of Cyclin-Dependent Kinase Inhibitor p27kip1 in Breast Cancer. *Cell Cycle*, **2004**, 3, 1072-1078	4.7	48
121	Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. *Carcinogenesis*, **2004**, 25, 2107-14	4.6	52
120	Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. *Cancer Gene Therapy*, **2004**, 11, 633-41	5.4	24
119	Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. *Oncogene*, **2004**, 23, 2188-96	9.2	38

118	The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. *Oncogene*, **2004**, 23, 8432-8	9.2	57
117	Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. *Oncogene*, **2004**, 23, 5958-67	9.2	113
116	Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. *Oncogene*, **2004**, 23, 6056-63	9.2	203
115	The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2. *Annals of the New York Academy of Sciences*, **2004**, 1030, 264-74	6.5	30
114	Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. *FEBS Letters*, **2004**, 574, 1-8	3.8	172
113	The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. *American Journal of Pathology*, **2004**, 165, 511-21	5.8	31
112	High mobility group A1 expression correlates with the histological grade of human glial tumors. *Oncology Reports*, **2004**, 11, 1209	3.5	7
111	High mobility group A1 expression correlates with the histological grade of human glial tumors. *Oncology Reports*, **2004**, 11, 1209-13	3.5	19
110	Loss of Hmga1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. *FASEB Journal*, **2003**, 17, 1496-8	0.9	53
109	HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. *Carcinogenesis*, **2003**, 24, 1191-8	4.6	69
108	A truncated HMGA1 gene induces proliferation of the 3T3-L1 pre-adipocytic cells: a model of human lipomas. *Carcinogenesis*, **2003**, 24, 1861-9	4.6	27
107	ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 5027-32	5.6	40
106	High-mobility group A1 proteins are overexpressed in human leukaemias. *Biochemical Journal*, **2003** , 372, 145-50	3.8	36
105	Derepression of HMGA2 Gene Expression in Retinoblastoma Is Associated with Cell Proliferation. *Molecular Medicine*, **2003**, 9, 154-165	6.2	17
104	Translational regulation of a novel testis-specific RNF4 transcript. *Molecular Reproduction and Development*, **2003**, 66, 1-7	2.6	35
103	High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms. *Journal of Gastroenterology*, **2003**, 38, 1144-9	6.9	26
102	Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. *Oncogene*, **2003**, 22, 246-55	9.2	45
101	Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells. *Oncogene*, **2003**, 22, 1087-97	9.2	53

100	Critical role of cyclin D3 in TSH-dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid gland. *Oncogene*, **2003**, 22, 7576-86	9.2	21
99	Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. *Molecular and Cellular Biology*, **2003**, 23, 2225-38	4.8	104
98	BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 5399-404	5.6	836
97	Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. *Molecular Endocrinology*, **2003**, 17, 1425-36		62
96	Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 1897-902	5.6	106
95	Regulation of BRCA1 transcription by specific single-stranded DNA binding factors. *Molecular and Cellular Biology*, **2003**, 23, 3774-87	4.8	52
94	Derepression of HMGA2 gene expression in retinoblastoma is associated with cell proliferation. *Molecular Medicine*, **2003**, 9, 154-65	6.2	16
93	An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. *Cancer Research*, **2003**, 63, 882-6	10.1	44
92	Molecular mechanisms of RET activation in human cancer. *Annals of the New York Academy of Sciences*, **2002**, 963, 116-21	6.5	107
91	Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. *International Journal of Cancer*, **2002**, 97, 608-14	7.5	37
90	Thyroid cell transformation requires the expression of the HMGA1 proteins. *Oncogene*, **2002**, 21, 2971-80	9.2	77
89	Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. *Oncogene*, **2002**, 21, 3190-8	9.2	181
88	HMGA1 and HMGA2 protein expression in mouse spermatogenesis. *Oncogene*, **2002**, 21, 3644-50	9.2	85
87	Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. *Nature Medicine*, **2002**, 8, 1136-44	50.5	601
86	Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. *Cell Cycle*, **2002**, 1, 394-400	4.7	110
85	RET activation and clinicopathologic features in poorly differentiated thyroid tumors. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 370-9	5.6	87
84	The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 364-9	5.6	81
83	Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 4728-35	5.6	118

82	ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 2525-31	5.6	46
81	PATZ attenuates the RNF4-mediated enhancement of androgen receptor-dependent transcription. *Journal of Biological Chemistry*, **2002**, 277, 3280-5	5.4	29
80	Diagnostic significance of high mobility group I(Y) protein expression in intraductal papillary mucinous tumors of the pancreas. *Pancreas*, **2002**, 25, 198-204	2.6	22
79	Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. *American Journal of Pathology*, **2002**, 160, 2157-67	5.8	122
78	Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. *American Journal of Pathology*, **2002**, 160, 247-54	5.8	89
77	The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. *Biochemical and Biophysical Research Communications*, **2002**, 290, 942-7	3.4	42
76	Molecular Mechanisms of RET Activation in Human Neoplasia **2002**, 176-183		
75	The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. *Cancer Research*, **2002**, 62, 1077-82	10.1	85
74	The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. *Cancer Research*, **2002**, 62, 2398-405	10.1	62
73	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. *Cancer Research*, **2002**, 62, 7284-90	10.1	425
72	High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. *International Journal of Cancer*, **2001**, 91, 147-151	7.5	6
71	The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. *Oncogene*, **2001**, 20, 209-18	9.2	54
70	The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane. *Oncogene*, **2001**, 20, 599-608	9.2	51
69	Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. *Oncogene*, **2001**, 20, 885-92	9.2	34
68	High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. *Oncogene*, **2001**, 20, 6132-41	9.2	81
67	RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. *Oncogene*, **2001**, 20, 6973-82	9.2	38
66	The RET receptor: function in development and dysfunction in congenital malformation. *Trends in Genetics*, **2001**, 17, 580-9	8.5	240
65	Critical role of the HMGI(Y) proteins in adipocytic cell growth and differentiation. *Molecular and Cellular Biology*, **2001**, 21, 2485-95	4.8	75

64	The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation. *Molecular Endocrinology*, **2001**, 15, 1838-52		47
63	RNF4 is a growth inhibitor expressed in germ cells but not in human testicular tumors. *American Journal of Pathology*, **2001**, 159, 1225-30	5.8	47
62	Rat protein tyrosine phosphatase eta physically interacts with the PDZ domains of syntenin. *FEBS Letters*, **2001**, 500, 41-4	3.8	27
61	Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. *Endocrine Reviews*, **2001**, 22, 631-56	27.2	355
60	High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. *International Journal of Cancer*, **2001**, 91, 147-51	7.5	72
59	RET/PTC activation in hyalinizing trabecular tumors of the thyroid. *American Journal of Surgical Pathology*, **2000**, 24, 1615-21	6.7	128
58	PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. *Oncogene*, **2000**, 19, 3146-55	9.2	124
57	The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. *Oncogene*, **2000**, 19, 5729-35	9.2	81
56	A 12q13 translocation involving the HMGI-C gene in richter transformation of a chronic lymphocytic leukemia. *Cancer Genetics and Cytogenetics*, **2000**, 119, 70-3		16
55	Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 3898-907	5.6	53
54	Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). *Molecular and Cellular Biology*, **2000**, 20, 9236-46	4.8	94
53	Pivotal role of the RB family proteins in in vitro thyroid cell transformation. *Experimental Cell Research*, **2000**, 260, 257-67	4.2	10
52	A novel member of the BTB/POZ family, PATZ, associates with the RNF4 RING finger protein and acts as a transcriptional repressor. *Journal of Biological Chemistry*, **2000**, 275, 7894-901	5.4	69
51	Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. *Oncogene*, **1999**, 18, 4860-9	9.2	45
50	Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation. *Oncogene*, **1999**, 18, 6241-51	9.2	42
49	Involvement of the HMGI(Y) gene in a microfollicular adenoma of the thyroid. *Genes Chromosomes and Cancer*, **1999**, 24, 286-289	5	9
48	A KRAB zinc finger protein gene is the potential target of 19q13 translocation in benign thyroid tumors **1999**, 26, 229-236		11
47	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the bcl-2 gene. *International Journal of Cancer*, **1999**, 81, 956-62	7.5	12

46	Different mutations of the RET gene cause different human tumoral diseases. *Biochimie*, **1999**, 81, 397-407	4.2	12
45	Sp1 and CTF/NF-1 transcription factors are involved in the basal expression of the Hmgi-c proximal promoter. *Biochemical and Biophysical Research Communications*, **1999**, 265, 439-47	3.4	15
44	Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. *Journal of Clinical Investigation*, **1999**, 104, 865-74	15.9	99
43	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the bcl-2 gene **1999**, 81, 956		1
42	Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. *Oncogene*, **1998**, 16, 2435-45	9.2	105
41	Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. *Oncogene*, **1998**, 17, 413-8	9.2	103
40	Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. *Oncogene*, **1998**, 17, 2851-61	9.2	88
39	HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. *Genes Chromosomes and Cancer*, **1998**, 23, 279-285	5	68
38	Genetic alterations in thyroid carcinoma associated with familial adenomatous polyposis: clinical implications and suggestions for early detection. *World Journal of Surgery*, **1998**, 22, 1231-6	3.3	67
37	Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. *Oncogene*, **1998**, 17, 377-85	9.2	48
36	Protein tyrosine phosphatase-eta expression is upregulated by the PKA-dependent and is downregulated by the PKC-dependent pathways in thyroid cells. *Experimental Cell Research*, **1998**, 245, 195-202	4.2	15
35	Identification and characterization of a novel RING-finger gene (RNF4) mapping at 4p16.3. *Genomics*, **1998**, 47, 258-65	4.3	24
34	Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. *Endocrinology*, **1998**, 139, 3613-9	4.8	30
33	The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 1003-6	5.6	70
32	Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 4094-100	5.6	37
31	Oncogene transformation of PC Cl3 clonal thyroid cell line induces an autonomous pattern of proliferation that correlates with a loss of basal and stimulated phosphotyrosine phosphatase activity. *Endocrinology*, **1997**, 138, 3756-63	4.8	19
30	Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. *Experimental Cell Research*, **1997**, 235, 62-70	4.2	50
29	Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. *Oncogene*, **1997**, 15, 1987-94	9.2	153

28	Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. *Oncogene*, **1997**, 15, 2687-98	9.2	88
27	Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. *Laryngoscope*, **1997**, 107, 95-100	3.6	210
26	Glial cell line-derived nenrotrophic factor (GDNF) stimulates ret activity. *Rendiconti Lincei*, **1997**, 8, 139-149	1.7	
25	Breakpoints of 19q13 translocations of benign thyroid tumors map within a 400 kilobase region. *Genes Chromosomes and Cancer*, **1997**, 20, 201-203	5	9
24	Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours. *European Journal of Endocrinology*, **1996**, 134, 177-83	6.5	41
23	Status and expression of the p16INK4 gene in human thyroid tumors and thyroid-tumor cell lines. *International Journal of Cancer*, **1996**, 67, 29-34	7.5	20
22	Ligand stimulation of a Ret chimeric receptor carrying the activating mutation responsible for the multiple endocrine neoplasia type 2B. *Journal of Biological Chemistry*, **1996**, 271, 29497-501	5.4	10
21	Somatostatin inhibits PC Cl3 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene. *Journal of Biological Chemistry*, **1996**, 271, 6129-36	5.4	55
20	Intracellular Signaling by the ret Tyrosine Kinase. *Medical Intelligence Unit*, **1996**, 37-59		1
19	Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. *European Journal of Endocrinology*, **1995**, 133, 513-22	6.5	46
18	Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. *International Journal of Cancer*, **1995**, 64, 171-5	7.5	62
17	Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. *Cancer*, **1994**, 73, 2206-12	6.4	106
16	Aberrant expression, function and localization of connexins in human esophageal carcinoma cell lines with different degrees of tumorigenicity. *Journal of Cancer Research and Clinical Oncology*, **1994**, 120, 445-53	4.9	24
15	Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. *Experimental Cell Research*, **1994**, 213, 398-403	4.2	21
14	Activation of the ret oncogene in human thyroid carcinomas. *Rendiconti Lincei*, **1993**, 4, 367-375	1.7	1
13	The PTC oncogene is able to dedifferentiate a rat thyroid epithelial cell line in culture. *Rendiconti Lincei*, **1992**, 3, 257-267	1.7	1
12	Comparison of multiple forms of the high mobility group I proteins in rodent and human cells. Identification of the human high mobility group I-C protein. *FEBS Journal*, **1991**, 198, 211-6		52
11	PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. *Cell*, **1990**, 60, 557-63	56.2	810

10	Thyrotropin receptor gene expression in oncogene-transfected rat thyroid cells: correlation between transformation, loss of thyrotropin-dependent growth, and loss of thyrotropin receptor gene expression. *Biochemical and Biophysical Research Communications*, **1990**, 173, 172-8	3.4	37
9	Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. *Experimental Cell Research*, **1989**, 184, 538-45	4.2	119
8	The block of thyroglobulin synthesis, which occurs upon transformation of rat thyroid epithelial cells, is at the transcriptional level and it is associated with methylation of the 5' flanking region of the gene. *Experimental Cell Research*, **1989**, 183, 277-83	4.2	13
7	Multipotential hemopoietic cell lines isolated from stem cell cultures infected with Friend virus complex (MuLV + F-SFFV) show presence of MuLV but not F-SFFV. *Leukemia Research*, **1986**, 10, 187-93	2.7	5
6	Transformation of rat thyroid epithelial cells by Kirsten murine sarcoma virus. *International Journal of Cancer*, **1981**, 28, 655-62	7.5	38
5	Only the Substitution of Methionine 918 with a Threonine and Not with Other Residues Activates RET Transforming Potential		5
4	Oncogene Transformation of PC Cl3 Clonal Thyroid Cell Line Induces an Autonomous Pattern of Proliferation That Correlates with a Loss of Basal and Stimulated Phosphotyrosine Phosphatase Activity		9
3	Thyroid cell transformation requires the expression of the HMGA1 proteins		1
2	Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas		1
1	Suramin potently inhibits binding of the mammalian high mobility group protein AT-hook 2 to DNA		1